Gene therapy trial: restored hearing in children with hereditary deafness

Al­though Palatin Tech­nolo­gies’ lead drug can­di­date missed a pair of pri­ma­ry end­points in a Phase III dry eye dis­ease tri­al, the com­pa­ny be­lieves there’s still

Har­ri­son and Star, an al­most 40-year-old phar­ma and health agency, is get­ting back to its sci­ence roots un­der its new­er lead­er­ship. The re­newed fo­cus on